A $2 million drug is about to hit the market
May 8, 2019

From the Wall Street Journal:

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

Novartis has yet to set a price for the gene therapy called Zolgensma, but executives say the drug's potential to cure spinal muscular atrophy, an inherited disease that typically kills babies before they turn two, justifies a seven-figure price.

Gene therapies target diseases that result from a faulty gene by introducing a working version into the body. They are attracting interest, both for their ability to cure otherwise devastating illnesses in one treatment and also for their high cost. Luxturna, the only gene therapy on sale in the U.S. so far to treat a form of inherited sight loss, costs $850,000 a patient.

Continue reading at the Wall Street Journal...

You may also like

IQ rates are dropping in many developed countries

"An intelligence crisis could undermine our problem-solving capacities and dim the prospects of the global economy."

Air pollution is a 'public health emergency'

"Air pollution may be damaging every organ and virtually every cell in the human body..."

Snakebites declared world's biggest hidden health crisis

"Scientists said research is urgently needed into the problem as they described snake bites as the world's biggest hidden health crisis."